Imugene Limited (AU:IMU) has released an update.
Imugene Limited, an immuno-oncology company, reported a strong cash position of $93 million and is advancing with multiple clinical trials, including a Phase 1b study for Azer-cel targeting blood cancers and a novel trial for bile tract cancer. The company’s innovative treatments are addressing significant unmet medical needs in oncology, with potential for their Azer-cel therapy to become the first approved allogeneic CAR T cell therapy for cancer by 2025.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
